NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

9 analysts have issued 12-month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' share price to reach $35.25 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

News articles about ITCI stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 6,540,000 shares, a drop of 21.9% from the January 15th total of 8,370,000 shares. Based on an average daily trading volume, of 2,790,000 shares, the short-interest ratio is presently 2.3 days. Currently, 14.0% of the shares of the company are short sold. View Intra-Cellular Therapies' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Crispr Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Gilead Sciences (GILD) and Clovis Oncology (CLVS).

Intra-Cellular Therapies' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (11.41%), State Street Corp (2.01%), Candriam Luxembourg S.C.A. (1.61%), Schroder Investment Management Group (1.36%), Rhenman & Partners Asset Management AB (0.90%) and DCF Advisers LLC (0.84%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Schroder Investment Management Group, Rhenman & Partners Asset Management AB, State Street Corp, Candriam Luxembourg S.C.A., Credit Suisse AG, Rafferty Asset Management LLC and New York State Common Retirement Fund. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including DCF Advisers LLC, FMR LLC, First Midwest Bank Trust Division, Goldman Sachs Group Inc., UBS Group AG, Raymond James & Associates, TD Asset Management Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $22.84.